Omeros Corporation’s 2-year extension of pass-through status for Omidria provided by Congress through the Consolidated Appropriations Act of 2018 expired Oct. 1.
Omeros requested confirmation of a separate payment status for the phenylephrine 1% and ketorolac 0.3% intraocular solution from the Centers for Medicare and Medicaid Services (CMS) and the Department of Health and Human Services for use in ambulatory surgery centers (ASCs) for the fourth quarter of 2020, according to a company press release.
Omidria meets the objective regulatory criteria from CMS for separate payment in the ASC
Uncategorized